Product information and disease descriptionProduct description
Phase of product development
18 evidence topics · 17 sources
Summary: development stage and regulatory timing
Lanifibranor is an investigational oral product in phase 3 development for adults with noncirrhotic MASH and F2 to F3 fibrosis. The last participant completed the final 72-week visit of the NATiV3 phase 3 trial, and NATiV3 topline results were expected in the fourth quarter of 2026. Inventiva states that, if the results are favorable, it anticipates a regulatory submission in the first half of 2027 under the FDA accelerated approval pathway and is preparing for a potential U.S. launch in 2028, subject to FDA approval. The FDA granted Fast Track designation and, in October 2020, Breakthrough Therapy designation, and the Chinese NMPA granted Breakthrough Therapy designation in December 2023. Company guidance for NATiV3 topline results changed across successive releases: from the second half of 2024 to the second half of 2025, the first half of 2026, the beginning of the second half of 2026, the second half of 2026, and the fourth quarter of 2026.
Regulatory status: Submission planned; NDA for accelerated approval planned for the first half of 2027
Launch: Anticipated in 2028
NATiV3 topline timing: fourth quarter of 2026, as of October 2026
NATiV3 last patient visit, September 2026
Approval status: not approved by any regulatory authority
Accelerated approval and conditional authorization: completion of the trial required for full approval
Planned phase 3 outcome trial in MASH with compensated cirrhosis
FDA Fast Track designation for NASH, September 2019
FDA Breakthrough Therapy designation for NASH, October 2020
FDA Fast Track designation extended to NASH with compensated cirrhosis, September 2021
China NMPA Breakthrough Therapy designation for MASH, December 2023
EU PRIME designation
No evidence found.